Consolidated Balance Sheets - USD ($)	Jul. 31, 2025	Jul. 31, 2024
Current assets:
Cash	$ 19,084	$ 2,379
Research and development rebate due from Australian government, net	0	22,625
Prepaid expenses and other current assets, net	30,639	31,939
Total current assets	49,723	56,943
Investment in Oragenics, Inc. common stock, at fair value	0	529,203
Total assets	49,723	586,146
Current liabilities:
Accounts payable and accrued wages	1,615,357	1,400,723
Accounts payable and accrued wages, officers	1,858,443	1,523,859
Accrued interest	421,440	223,754
Asset purchase liability	1,125,026	1,125,026
Notes payable, officers and directors	100,000	100,000
Notes payable, net of unamortized debt discounts and closing costs of $512 and $38,134	1,884,155	1,546,533
Total current liabilities	7,004,421	5,919,895
Commitments and contingencies
Stockholders' deficit:
Preferred stock, $0.001 par value, 100,000,000 shares authorized, no shares issued or outstanding	0	0
Common stock, $0.001 par value, 500,000,000 shares authorized, 96,709,763 shares issued and outstanding	96,710	96,710
Additional paid-in-capital	55,694,429	55,572,687
Accumulated deficit	(62,745,837)	(61,003,146)
Total stockholders' deficit	(6,954,698)	(5,333,749)
Total liabilities and stockholders' deficit	$ 49,723	$ 586,146